ViiV redeems voucher for fast FDA review of HIV combinationViiV Healthcare has applied for a fast US review of its single-tablet, two drug HIV drug regimen of Share XViiV redeems voucher for fast FDA review of HIV combinationhttps://pharmaphorum.com/news/viiv-redeems-voucher-for-fast-fda-review-of-hiv-combination/
Merck aims for first line kidney cancer use for Keytruda comboMerck & Co is to request licences for its Keytruda immunotherapy in kidney cancer, following trial results showing Share XMerck aims for first line kidney cancer use for Keytruda combohttps://pharmaphorum.com/news/merck-aims-for-first-line-kidney-cancer-use-for-keytruda-combo/
Amgen invests £50m in UK genetics firm Oxford NanoporeBiotech giant Amgen has ploughed £50 million into a genetic sequencing company to support the development of its Share XAmgen invests £50m in UK genetics firm Oxford Nanoporehttps://pharmaphorum.com/news/amgen-invests-50m-in-uk-genetics-firm-oxford-nanopore/
Balancing expectations: An unmet need in the orphan disease arenaThere are between 6000 and 8000 rare diseases in the world, and one in ten people in Europe Share XBalancing expectations: An unmet need in the orphan disease arenahttps://pharmaphorum.com/views-analysis-market-access/balancing-expectations-rare-disease-arena/
Calliditas pushing on with kidney disease drug after IPO successCalliditas Therapeutics has just pulled off the largest biotech IPO in Europe this year and is using it Share XCalliditas pushing on with kidney disease drug after IPO successhttps://pharmaphorum.com/r-d/views-analysis-r-d/calliditas-pushing-kidney-disease-drug-ipo-success/
Digital health round-up: Pfizer appoints chief digital officer and morePfizer has appointed a chief digital officer because of the growing importance of digital technology in its R&D Share XDigital health round-up: Pfizer appoints chief digital officer and morehttps://pharmaphorum.com/views-and-analysis/digital-health-round-up-pfizer-appoints-chief-digital-officer-and-more/
CAR-Ts – a new weapon in the fight against cancerCAR-T – or Chimeric Antigen Receptor T-cell therapies herald a new wave of therapies in cancer. CAR-T therapies Share XCAR-Ts – a new weapon in the fight against cancerhttps://pharmaphorum.com/views-and-analysis/car-ts-a-new-weapon-in-the-fight-against-cancer/
How to achieve digital success in pharma’s communicationsDemystifying what digital means, empowering people to ‘think digitally’ and acting with confidence are game changing factors for Share XHow to achieve digital success in pharma’s communicationshttps://pharmaphorum.com/views-analysis-digital/achieve-digital-success-pharma/
Future-proofing pharma with a multichannel approach to sales and marketingDeploying a multichannel approach to marketing, backed by the use of advanced analytics, could help pharma evolve and Share XFuture-proofing pharma with a multichannel approach to sales and marketinghttps://pharmaphorum.com/views-analysis-sales-marketing/multichannel-marketing-sales-pharma/
Realising the biotech promise: addressing the path to market Share XRealising the biotech promise: addressing the path to markethttps://pharmaphorum.com/market-access-2/addressing-the-path-to-market/
10/12/2018Digital therapeutics and healthcare innovation Share XDigital therapeutics and healthcare innovationhttps://pharmaphorum.com/debates-insight-digital/digital-therapeutics-and-healthcare-innovation/
How to make digital work in medtech Share XHow to make digital work in medtechhttps://pharmaphorum.com/webinars/webinars-on-demand/make-digital-work-medtech/
The changing face of pharmaceutical launchesThe industry has experienced a sustained period of change since its blockbuster heyday in the 1990s and continues Share XThe changing face of pharmaceutical launcheshttps://pharmaphorum.com/market-access-2/digital-transforming-pharmaceutical-launches/
Remote HCP engagement – still a struggle for life science companiesLife science companies are failing to achieve their full digital potential, particularly when it comes to the use Share XRemote HCP engagement – still a struggle for life science companieshttps://pharmaphorum.com/white-papers/remote-hcps-engagement-life-science/
Medical meetings and what HCPs wantThe healthcare professional (HCP) meeting landscape is evolving, but even as it adjusts to the demands of the Share XMedical meetings and what HCPs wanthttps://pharmaphorum.com/whitepapers/medical-meetings-and-what-hcps-want/
Raising the bar in liver cancer therapy Share XRaising the bar in liver cancer therapyhttps://pharmaphorum.com/oncology/insights-oncology/raising-bar-liver-cancer-therapy/
Eisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s success Share XEisai’s EMEA CEO Gary Hendler on why quality of life is key to Lenvima’s successhttps://pharmaphorum.com/oncology/insights-oncology/eisais-emea-ceo-gary-hendler-lenvimas-success/
Part three: Oncology shaping the future of personalised healthcare Share XPart three: Oncology shaping the future of personalised healthcarehttps://pharmaphorum.com/video/part-three-oncology-shaping-future-personalised-healthcare/
An Interview with Alexander Zuern, Device Testing Manager, from Novartis Share XAn Interview with Alexander Zuern, Device Testing Manager, from Novartishttps://pharmaphorum.com/partner-content/an-interview-with-alexander-zuern-device-testing-manager-from-novartis/
Preliminary Attendee List Released for Orphan Drugs & Rare Diseases Conference Share XPreliminary Attendee List Released for Orphan Drugs & Rare Diseases Conferencehttps://pharmaphorum.com/partner-content/preliminary-attendee-list-released-for-orphan-drugs-rare-diseases-conference/
Spotlight sessions at the upcoming Lyophilization USA Conference Share XSpotlight sessions at the upcoming Lyophilization USA Conferencehttps://pharmaphorum.com/partner-content/spotlight-sessions-at-the-upcoming-lyophilization-usa-conference/
SMi’s release speaker interview Anita Burrell, speaker at Biosimilars USA Share XSMi’s release speaker interview Anita Burrell, speaker at Biosimilars USAhttps://pharmaphorum.com/partner-content/smis-release-speaker-interview-anita-burrell-speaker-at-biosimilars-usa/
Carina Schey, University of Groningen, Orphan Drugs & Rare Diseases Chair Invitation Share XCarina Schey, University of Groningen, Orphan Drugs & Rare Diseases Chair Invitationhttps://pharmaphorum.com/partner-content/carina-schey-university-of-groningen-orphan-drugs-rare-diseases-chair-invitation/
Corporate Communications chief of Astellas, Jo Taylor moves to Cello Health Communications Share XCorporate Communications chief of Astellas, Jo Taylor moves to Cello Health Communicationshttps://pharmaphorum.com/partner-content/corporate-communications-chief-of-astellas-jo-taylor-moves-to-cello-health-communications/
